Personalized Medicine and Epigenomics Market, Global Outlook and Forecast 2022-2028

March 2022 | 116 pages | ID: PBB1061D33B9EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Personalized Medicine and Epigenomics in Global, including the following market information:

Global Personalized Medicine and Epigenomics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Personalized Medicine and Epigenomics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Reagents Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Personalized Medicine and Epigenomics include Abbott Laboratories, Affymetrix, Agilent Technologies, Astellas Pharmaceuticals, BAYER AG, Bio Vision, Celgene Corp., Emd Millipore and Epigenomics AG, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Personalized Medicine and Epigenomics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Personalized Medicine and Epigenomics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Personalized Medicine and Epigenomics Market Segment Percentages, by Type, 2021 (%)

• Reagents
• Kits
• Instruments
• Enzymes
• Services

Global Personalized Medicine and Epigenomics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Personalized Medicine and Epigenomics Market Segment Percentages, by Application, 2021 (%)

• Oncology
• Non-Oncology
• Cancer Drug Technology

Global Personalized Medicine and Epigenomics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Personalized Medicine and Epigenomics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Personalized Medicine and Epigenomics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Personalized Medicine and Epigenomics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Abbott Laboratories
• Affymetrix
• Agilent Technologies
• Astellas Pharmaceuticals
• BAYER AG
• Bio Vision
• Celgene Corp.
• Emd Millipore
• Epigenomics AG
• Epigentex
• Envivo Pharmaceuticals (Forum Pharmaceutricals)
• Gilead Sciences
• Glaxosmithkline
• Illumina Inc.
• Johnson & Johnson
• Karus Therapeutics Limited
• Laboratory Corp. Of America Holdings
• LES Laboratoires Servier
• Merck
• Naturewise Biotech & Medicals Corp.
• Novartis Pharma AG
• Oncolys Biopharma Inc.
• Orchid Chemicals & Pharmaceuticals Limited
• Progen Pharmaceuticals Limited
• Quest Diagnostics
• Roche Holding AG
• Rubicon Genomics
• Takeda Pharmaceutical Company Limited

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Personalized Medicine and Epigenomics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Personalized Medicine and Epigenomics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL PERSONALIZED MEDICINE AND EPIGENOMICS OVERALL MARKET SIZE

2.1 Global Personalized Medicine and Epigenomics Market Size: 2021 VS 2028
2.2 Global Personalized Medicine and Epigenomics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Personalized Medicine and Epigenomics Players in Global Market
3.2 Top Global Personalized Medicine and Epigenomics Companies Ranked by Revenue
3.3 Global Personalized Medicine and Epigenomics Revenue by Companies
3.4 Top 3 and Top 5 Personalized Medicine and Epigenomics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Personalized Medicine and Epigenomics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Personalized Medicine and Epigenomics Players in Global Market
  3.6.1 List of Global Tier 1 Personalized Medicine and Epigenomics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Personalized Medicine and Epigenomics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Personalized Medicine and Epigenomics Market Size Markets, 2021 & 2028
  4.1.2 Reagents
  4.1.3 Kits
  4.1.4 Instruments
  4.1.5 Enzymes
  4.1.6 Services
4.2 By Type - Global Personalized Medicine and Epigenomics Revenue & Forecasts
  4.2.1 By Type - Global Personalized Medicine and Epigenomics Revenue, 2017-2022
  4.2.2 By Type - Global Personalized Medicine and Epigenomics Revenue, 2023-2028
  4.2.3 By Type - Global Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Personalized Medicine and Epigenomics Market Size, 2021 & 2028
  5.1.2 Oncology
  5.1.3 Non-Oncology
  5.1.4 Cancer Drug Technology
5.2 By Application - Global Personalized Medicine and Epigenomics Revenue & Forecasts
  5.2.1 By Application - Global Personalized Medicine and Epigenomics Revenue, 2017-2022
  5.2.2 By Application - Global Personalized Medicine and Epigenomics Revenue, 2023-2028
  5.2.3 By Application - Global Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Personalized Medicine and Epigenomics Market Size, 2021 & 2028
6.2 By Region - Global Personalized Medicine and Epigenomics Revenue & Forecasts
  6.2.1 By Region - Global Personalized Medicine and Epigenomics Revenue, 2017-2022
  6.2.2 By Region - Global Personalized Medicine and Epigenomics Revenue, 2023-2028
  6.2.3 By Region - Global Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Personalized Medicine and Epigenomics Revenue, 2017-2028
  6.3.2 US Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.3.3 Canada Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.3.4 Mexico Personalized Medicine and Epigenomics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Personalized Medicine and Epigenomics Revenue, 2017-2028
  6.4.2 Germany Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.4.3 France Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.4.4 U.K. Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.4.5 Italy Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.4.6 Russia Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.4.7 Nordic Countries Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.4.8 Benelux Personalized Medicine and Epigenomics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Personalized Medicine and Epigenomics Revenue, 2017-2028
  6.5.2 China Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.5.3 Japan Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.5.4 South Korea Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.5.5 Southeast Asia Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.5.6 India Personalized Medicine and Epigenomics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Personalized Medicine and Epigenomics Revenue, 2017-2028
  6.6.2 Brazil Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.6.3 Argentina Personalized Medicine and Epigenomics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Personalized Medicine and Epigenomics Revenue, 2017-2028
  6.7.2 Turkey Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.7.3 Israel Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.7.4 Saudi Arabia Personalized Medicine and Epigenomics Market Size, 2017-2028
  6.7.5 UAE Personalized Medicine and Epigenomics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Abbott Laboratories
  7.1.1 Abbott Laboratories Corporate Summary
  7.1.2 Abbott Laboratories Business Overview
  7.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Major Product Offerings
  7.1.4 Abbott Laboratories Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.1.5 Abbott Laboratories Key News
7.2 Affymetrix
  7.2.1 Affymetrix Corporate Summary
  7.2.2 Affymetrix Business Overview
  7.2.3 Affymetrix Personalized Medicine and Epigenomics Major Product Offerings
  7.2.4 Affymetrix Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.2.5 Affymetrix Key News
7.3 Agilent Technologies
  7.3.1 Agilent Technologies Corporate Summary
  7.3.2 Agilent Technologies Business Overview
  7.3.3 Agilent Technologies Personalized Medicine and Epigenomics Major Product Offerings
  7.3.4 Agilent Technologies Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.3.5 Agilent Technologies Key News
7.4 Astellas Pharmaceuticals
  7.4.1 Astellas Pharmaceuticals Corporate Summary
  7.4.2 Astellas Pharmaceuticals Business Overview
  7.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Major Product Offerings
  7.4.4 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.4.5 Astellas Pharmaceuticals Key News
7.5 BAYER AG
  7.5.1 BAYER AG Corporate Summary
  7.5.2 BAYER AG Business Overview
  7.5.3 BAYER AG Personalized Medicine and Epigenomics Major Product Offerings
  7.5.4 BAYER AG Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.5.5 BAYER AG Key News
7.6 Bio Vision
  7.6.1 Bio Vision Corporate Summary
  7.6.2 Bio Vision Business Overview
  7.6.3 Bio Vision Personalized Medicine and Epigenomics Major Product Offerings
  7.6.4 Bio Vision Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.6.5 Bio Vision Key News
7.7 Celgene Corp.
  7.7.1 Celgene Corp. Corporate Summary
  7.7.2 Celgene Corp. Business Overview
  7.7.3 Celgene Corp. Personalized Medicine and Epigenomics Major Product Offerings
  7.7.4 Celgene Corp. Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.7.5 Celgene Corp. Key News
7.8 Emd Millipore
  7.8.1 Emd Millipore Corporate Summary
  7.8.2 Emd Millipore Business Overview
  7.8.3 Emd Millipore Personalized Medicine and Epigenomics Major Product Offerings
  7.8.4 Emd Millipore Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.8.5 Emd Millipore Key News
7.9 Epigenomics AG
  7.9.1 Epigenomics AG Corporate Summary
  7.9.2 Epigenomics AG Business Overview
  7.9.3 Epigenomics AG Personalized Medicine and Epigenomics Major Product Offerings
  7.9.4 Epigenomics AG Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.9.5 Epigenomics AG Key News
7.10 Epigentex
  7.10.1 Epigentex Corporate Summary
  7.10.2 Epigentex Business Overview
  7.10.3 Epigentex Personalized Medicine and Epigenomics Major Product Offerings
  7.10.4 Epigentex Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.10.5 Epigentex Key News
7.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
  7.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Corporate Summary
  7.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
  7.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Major Product Offerings
  7.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Key News
7.12 Gilead Sciences
  7.12.1 Gilead Sciences Corporate Summary
  7.12.2 Gilead Sciences Business Overview
  7.12.3 Gilead Sciences Personalized Medicine and Epigenomics Major Product Offerings
  7.12.4 Gilead Sciences Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.12.5 Gilead Sciences Key News
7.13 Glaxosmithkline
  7.13.1 Glaxosmithkline Corporate Summary
  7.13.2 Glaxosmithkline Business Overview
  7.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Major Product Offerings
  7.13.4 Glaxosmithkline Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.13.5 Glaxosmithkline Key News
7.14 Illumina Inc.
  7.14.1 Illumina Inc. Corporate Summary
  7.14.2 Illumina Inc. Business Overview
  7.14.3 Illumina Inc. Personalized Medicine and Epigenomics Major Product Offerings
  7.14.4 Illumina Inc. Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.14.5 Illumina Inc. Key News
7.15 Johnson & Johnson
  7.15.1 Johnson & Johnson Corporate Summary
  7.15.2 Johnson & Johnson Business Overview
  7.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Major Product Offerings
  7.15.4 Johnson & Johnson Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.15.5 Johnson & Johnson Key News
7.16 Karus Therapeutics Limited
  7.16.1 Karus Therapeutics Limited Corporate Summary
  7.16.2 Karus Therapeutics Limited Business Overview
  7.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Major Product Offerings
  7.16.4 Karus Therapeutics Limited Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.16.5 Karus Therapeutics Limited Key News
7.17 Laboratory Corp. Of America Holdings
  7.17.1 Laboratory Corp. Of America Holdings Corporate Summary
  7.17.2 Laboratory Corp. Of America Holdings Business Overview
  7.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Major Product Offerings
  7.17.4 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.17.5 Laboratory Corp. Of America Holdings Key News
7.18 LES Laboratoires Servier
  7.18.1 LES Laboratoires Servier Corporate Summary
  7.18.2 LES Laboratoires Servier Business Overview
  7.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Major Product Offerings
  7.18.4 LES Laboratoires Servier Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.18.5 LES Laboratoires Servier Key News
7.19 Merck
  7.19.1 Merck Corporate Summary
  7.19.2 Merck Business Overview
  7.19.3 Merck Personalized Medicine and Epigenomics Major Product Offerings
  7.19.4 Merck Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.19.5 Merck Key News
7.20 Naturewise Biotech & Medicals Corp.
  7.20.1 Naturewise Biotech & Medicals Corp. Corporate Summary
  7.20.2 Naturewise Biotech & Medicals Corp. Business Overview
  7.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Major Product Offerings
  7.20.4 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.20.5 Naturewise Biotech & Medicals Corp. Key News
7.21 Novartis Pharma AG
  7.21.1 Novartis Pharma AG Corporate Summary
  7.21.2 Novartis Pharma AG Business Overview
  7.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Major Product Offerings
  7.21.4 Novartis Pharma AG Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.21.5 Novartis Pharma AG Key News
7.22 Oncolys Biopharma Inc.
  7.22.1 Oncolys Biopharma Inc. Corporate Summary
  7.22.2 Oncolys Biopharma Inc. Business Overview
  7.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Major Product Offerings
  7.22.4 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.22.5 Oncolys Biopharma Inc. Key News
7.23 Orchid Chemicals & Pharmaceuticals Limited
  7.23.1 Orchid Chemicals & Pharmaceuticals Limited Corporate Summary
  7.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview
  7.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Major Product Offerings
  7.23.4 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.23.5 Orchid Chemicals & Pharmaceuticals Limited Key News
7.24 Progen Pharmaceuticals Limited
  7.24.1 Progen Pharmaceuticals Limited Corporate Summary
  7.24.2 Progen Pharmaceuticals Limited Business Overview
  7.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Major Product Offerings
  7.24.4 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.24.5 Progen Pharmaceuticals Limited Key News
7.25 Quest Diagnostics
  7.25.1 Quest Diagnostics Corporate Summary
  7.25.2 Quest Diagnostics Business Overview
  7.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Major Product Offerings
  7.25.4 Quest Diagnostics Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.25.5 Quest Diagnostics Key News
7.26 Roche Holding AG
  7.26.1 Roche Holding AG Corporate Summary
  7.26.2 Roche Holding AG Business Overview
  7.26.3 Roche Holding AG Personalized Medicine and Epigenomics Major Product Offerings
  7.26.4 Roche Holding AG Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.26.5 Roche Holding AG Key News
7.27 Rubicon Genomics
  7.27.1 Rubicon Genomics Corporate Summary
  7.27.2 Rubicon Genomics Business Overview
  7.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Major Product Offerings
  7.27.4 Rubicon Genomics Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.27.5 Rubicon Genomics Key News
7.28 Takeda Pharmaceutical Company Limited
  7.28.1 Takeda Pharmaceutical Company Limited Corporate Summary
  7.28.2 Takeda Pharmaceutical Company Limited Business Overview
  7.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Major Product Offerings
  7.28.4 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Revenue in Global Market (2017-2022)
  7.28.5 Takeda Pharmaceutical Company Limited Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Personalized Medicine and Epigenomics Market Opportunities & Trends in Global Market
Table 2. Personalized Medicine and Epigenomics Market Drivers in Global Market
Table 3. Personalized Medicine and Epigenomics Market Restraints in Global Market
Table 4. Key Players of Personalized Medicine and Epigenomics in Global Market
Table 5. Top Personalized Medicine and Epigenomics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Personalized Medicine and Epigenomics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Personalized Medicine and Epigenomics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Personalized Medicine and Epigenomics Product Type
Table 9. List of Global Tier 1 Personalized Medicine and Epigenomics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Personalized Medicine and Epigenomics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Personalized Medicine and Epigenomics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Personalized Medicine and Epigenomics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Personalized Medicine and Epigenomics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Personalized Medicine and Epigenomics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Personalized Medicine and Epigenomics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Personalized Medicine and Epigenomics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2023-2028
Table 30. Abbott Laboratories Corporate Summary
Table 31. Abbott Laboratories Personalized Medicine and Epigenomics Product Offerings
Table 32. Abbott Laboratories Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 33. Affymetrix Corporate Summary
Table 34. Affymetrix Personalized Medicine and Epigenomics Product Offerings
Table 35. Affymetrix Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 36. Agilent Technologies Corporate Summary
Table 37. Agilent Technologies Personalized Medicine and Epigenomics Product Offerings
Table 38. Agilent Technologies Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 39. Astellas Pharmaceuticals Corporate Summary
Table 40. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product Offerings
Table 41. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 42. BAYER AG Corporate Summary
Table 43. BAYER AG Personalized Medicine and Epigenomics Product Offerings
Table 44. BAYER AG Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 45. Bio Vision Corporate Summary
Table 46. Bio Vision Personalized Medicine and Epigenomics Product Offerings
Table 47. Bio Vision Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 48. Celgene Corp. Corporate Summary
Table 49. Celgene Corp. Personalized Medicine and Epigenomics Product Offerings
Table 50. Celgene Corp. Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 51. Emd Millipore Corporate Summary
Table 52. Emd Millipore Personalized Medicine and Epigenomics Product Offerings
Table 53. Emd Millipore Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 54. Epigenomics AG Corporate Summary
Table 55. Epigenomics AG Personalized Medicine and Epigenomics Product Offerings
Table 56. Epigenomics AG Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 57. Epigentex Corporate Summary
Table 58. Epigentex Personalized Medicine and Epigenomics Product Offerings
Table 59. Epigentex Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 60. Envivo Pharmaceuticals (Forum Pharmaceutricals) Corporate Summary
Table 61. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product Offerings
Table 62. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 63. Gilead Sciences Corporate Summary
Table 64. Gilead Sciences Personalized Medicine and Epigenomics Product Offerings
Table 65. Gilead Sciences Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 66. Glaxosmithkline Corporate Summary
Table 67. Glaxosmithkline Personalized Medicine and Epigenomics Product Offerings
Table 68. Glaxosmithkline Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 69. Illumina Inc. Corporate Summary
Table 70. Illumina Inc. Personalized Medicine and Epigenomics Product Offerings
Table 71. Illumina Inc. Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 72. Johnson & Johnson Corporate Summary
Table 73. Johnson & Johnson Personalized Medicine and Epigenomics Product Offerings
Table 74. Johnson & Johnson Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 75. Karus Therapeutics Limited Corporate Summary
Table 76. Karus Therapeutics Limited Personalized Medicine and Epigenomics Product Offerings
Table 77. Karus Therapeutics Limited Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 78. Laboratory Corp. Of America Holdings Corporate Summary
Table 79. Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product Offerings
Table 80. Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 81. LES Laboratoires Servier Corporate Summary
Table 82. LES Laboratoires Servier Personalized Medicine and Epigenomics Product Offerings
Table 83. LES Laboratoires Servier Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 84. Merck Corporate Summary
Table 85. Merck Personalized Medicine and Epigenomics Product Offerings
Table 86. Merck Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 87. Naturewise Biotech & Medicals Corp. Corporate Summary
Table 88. Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Product Offerings
Table 89. Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 90. Novartis Pharma AG Corporate Summary
Table 91. Novartis Pharma AG Personalized Medicine and Epigenomics Product Offerings
Table 92. Novartis Pharma AG Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 93. Oncolys Biopharma Inc. Corporate Summary
Table 94. Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product Offerings
Table 95. Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 96. Orchid Chemicals & Pharmaceuticals Limited Corporate Summary
Table 97. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Product Offerings
Table 98. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 99. Progen Pharmaceuticals Limited Corporate Summary
Table 100. Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Product Offerings
Table 101. Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 102. Quest Diagnostics Corporate Summary
Table 103. Quest Diagnostics Personalized Medicine and Epigenomics Product Offerings
Table 104. Quest Diagnostics Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 105. Roche Holding AG Corporate Summary
Table 106. Roche Holding AG Personalized Medicine and Epigenomics Product Offerings
Table 107. Roche Holding AG Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 108. Rubicon Genomics Corporate Summary
Table 109. Rubicon Genomics Personalized Medicine and Epigenomics Product Offerings
Table 110. Rubicon Genomics Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)
Table 111. Takeda Pharmaceutical Company Limited Corporate Summary
Table 112. Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product Offerings
Table 113. Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Personalized Medicine and Epigenomics Segment by Type in 2021
Figure 2. Personalized Medicine and Epigenomics Segment by Application in 2021
Figure 3. Global Personalized Medicine and Epigenomics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Personalized Medicine and Epigenomics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Personalized Medicine and Epigenomics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Personalized Medicine and Epigenomics Revenue in 2021
Figure 8. By Type - Global Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028
Figure 12. US Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028
Figure 16. Germany Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 17. France Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028
Figure 24. China Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 28. India Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028
Figure 30. Brazil Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Personalized Medicine and Epigenomics Revenue Market Share, 2017-2028
Figure 33. Turkey Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Personalized Medicine and Epigenomics Revenue, (US$, Mn), 2017-2028
Figure 37. Abbott Laboratories Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Affymetrix Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Agilent Technologies Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. BAYER AG Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bio Vision Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Celgene Corp. Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Emd Millipore Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Epigenomics AG Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Epigentex Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Gilead Sciences Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Glaxosmithkline Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Illumina Inc. Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Johnson & Johnson Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Karus Therapeutics Limited Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. LES Laboratoires Servier Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. Merck Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 57. Novartis Pharma AG Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 58. Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 59. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 60. Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 61. Quest Diagnostics Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 62. Roche Holding AG Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 63. Rubicon Genomics Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 64. Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)